Home | Investor Relations
Stock Quote (NASDAQ: NSTG)
- 0.70
Day High:
Day Low:
4:00 PM ET on Dec 19, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Search Investor Relations

Investor Relations

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs or copy number variations simultaneously with high sensitivity and precision, enabling a wide variety of basic and translational research applications, including biomarker discovery and validation. The Prosigna™ Breast Cancer Prognostic Gene Signature Assay, based on the PAM50 gene signature, is the first nCounter-based in vitro diagnostic kit and is available in the European Union and other countries that recognize the CE Mark and in which Prosigna is registered.

Key Publication

ARTICLEAug 01, 2013
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
Dowsett M. et al., Journal of Clinical Oncology August 1, 2013 vol. 31 no. 22 2783-2790

View all »Events & Webcasts

WEBCASTNov 20, 2014 at 11:00 AM ET
Canaccord Genuity Medical Technology and Diagnostics Forum
WEBCASTNov 04, 2014 at 4:30 PM ET
Nanostring 2014 Third Quarter Financial Results
WEBCASTSep 10, 2014 at 1:30 PM ET
2014 Morgan Stanley Global Healthcare Conference